Which stage is severe and destructive and overproduces urate and tophi; requires pharm treatment?

• A. Acute gout
• B. Intercritical gout
• C. Chronic tophaceous gout
• D. Asymptomatic hyperuricemia

Answer: (C)

Chronic tophaceous gout is the late, severe stage where urate crystals form tophi in soft tissues, joints suffer ongoing bone and cartilage destruction, and uric acid levels remain high over time. This combination leads to visible tophi, deformities, and functional impairment, so it requires pharmacologic urate-lowering therapy to reduce serum urate to goal levels and prevent further damage. In this stage, treatment aims not only to control symptoms but to modify the disease course by lowering urate production or promoting urate excretion, with options like xanthine oxidase inhibitors (e.g., allopurinol, febuxostat), uricosurics if appropriate, and in refractory cases, pegloticase. By contrast, acute gout involves short-lived inflammatory flares; the intercritical phase is the asymptomatic interval between flares; and asymptomatic hyperuricemia means high uric acid without symptoms, so they don’t yet demand long-term urate-lowering therapy.